Pivotal Phase 3 Clinical Trial

Aesculap Biologics, LLC Reaches Halfway Mark for Enrollment in Pivotal Phase 3 Clinical Trial of NOVOCART® 3D in Patients with Articular Cartilage Defects of the Knee

CENTER VALLEY, Pa., Feb. 28, 2019 /PRNewswire/ — Aesculap Biologics, LLC (“Aesculap Biologics”) announced today that it has successfully achieved 50 percent enrollment…